- Conditions
- Healthy Participants
- Interventions
- PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 1,667
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Interventions
- YG1699, Dapagliflozin
- Drug
- Lead sponsor
- Youngene Therapeutics Inc., Ltd.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetic Foot Ulcers
- Interventions
- FGF-1 141
- Drug
- Lead sponsor
- Phage Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Hypertension
- Interventions
- baxdrostat (formerly CIN-107) oral solution
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care
- Drug · Behavioral
- Lead sponsor
- Kanecia Obie Zimmerman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Cancers
- Interventions
- Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Plantar Fasciitis
- Interventions
- DAXI 80 U, DAXI 120 U, Placebo
- Biological · Other
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Tobacco Use Cessation
- Interventions
- Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test
- Drug · Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Kidney Diseases, Obesity
- Interventions
- SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
- Behavioral · Drug
- Lead sponsor
- Srinvasan Beddhu
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Stanford, California • Salt Lake City, Utah
- Conditions
- Cytopenia
- Interventions
- Emapalumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteer
- Interventions
- TAK-951, TAK-951 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
- Interventions
- Electronic health record best practice alert
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- Female only
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Acute Coronary Syndrome, Depression
- Interventions
- Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
- Behavioral · Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-RPGR
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 8 Years to 50 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- HLX43 DOSE 1 (2.0 mg/kg), HLX43 DOSE 2 (2.5 mg/kg)
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
- Drug · Other
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- Up to 70 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Interventions
- brentuximab vedotin
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Duarte, California • New York, New York
- Conditions
- Substance-Related Disorders
- Interventions
- Letters
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumors
- Interventions
- Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
- Drug
- Lead sponsor
- Parth Patel
- Other
- Eligibility
- Up to 10 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- HIV Infection
- Interventions
- Atazanavir + Ritonavir + Combivir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- West Palm Beach, Florida • Houston, Texas
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
- Procedure · Other · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2075
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
- Conditions
- Follicular Lymphoma
- Interventions
- Bendamustine, Rituximab, Tazemetostat
- Drug
- Lead sponsor
- Vaishalee Kenkre
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New Brunswick, New Jersey • Columbus, Ohio + 1 more